Esomeprazole Magnesium For Suspension
NDC Package 69097-508-31

11-digit billing NDC: 69097050831 · Billing unit: EA · 30 EA per package

Package Information

Esomeprazole Magnesium for suspensions is esomeprazole magnesium for delayed release oral suspension is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. This formulation utilizes a for suspension delivery system. Marketed by Cipla Usa Inc., this product is identified by NDC 69097-508 and is authorized under FDA application ANDA217714.

Identification & Billing

NDC Package Code
69097-508-31
Package Description
30 FOR SUSPENSION in 1 CARTON
Product Code
11-Digit Billing Format
69097050831
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
30 EA
RxNorm Crosswalk
  • RxCUI: 1297658 - esomeprazole 2.5 MG Granules for Delayed Release Oral Suspension
  • RxCUI: 1297658 - esomeprazole 2.5 MG Granules for Oral Suspension
  • RxCUI: 1297658 - esomeprazole (as esomeprazole magnesium) 2.5 MG Granules for Delayed Release Oral Suspension
  • RxCUI: 1297761 - esomeprazole 5 MG Granules for Delayed Release Oral Suspension
  • RxCUI: 1297761 - esomeprazole 5 MG Granules for Oral Suspension

Clinical Specifications

Proprietary Name
Esomeprazole Magnesium
Non-Proprietary Name
Esomeprazole Magnesium
Substance Name
Esomeprazole Magnesium Dihydrate
Dosage Form
For Suspension - A product, usually a solid, intended for suspension prior to administration.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Esomeprazole magnesium for delayed release oral suspension is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6.2)].For information about contraindications of amoxicillin and clarithromycin, indicated in combination with esomeprazole magnesium for delayed release oral suspension for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information.Proton pump inhibitors (PPIs), including Esomeprazole magnesium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)].

Regulatory & Marketing

Labeler Name
Cipla Usa Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA217714
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-07-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69097-508-31 identifies a specific commercial package of 30 for suspension in 1 carton of Esomeprazole Magnesium, a human prescription drug labeled by Cipla Usa Inc.. This for suspension is formulated for oral use and contains esomeprazole magnesium dihydrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cipla Usa Inc. on January 07, 2025. The current certification is valid through December 31, 2026.

How is this Cipla Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69097050831. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69097-508-31
11-Digit CMS (5-4-2)
69097-0508-31

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.